Skip to main content
SpringerLink
Log in

Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy

  • Chapter
  • First Online:
BRAF Targets in Melanoma

Part of the book series: Cancer Drug Discovery and Development ((CDD&D,volume 82))

  • 931 Accesses

Abstract

The incidence of melanoma continues to increase with the vast majority of skin cancer-related deaths attributable to melanoma. Historically, response rates for systemic treatments for metastatic melanoma were only 5–20 % for chemotherapy, and the prognosis of patients with metastatic disease was extremely poor. The discovery of BRAF mutations in melanoma led to the development of BRAF-directed therapy which dramatically increased response rates. However, most patients treated with BRAF inhibitors eventually show disease recurrence, and it is now believed that combination therapies based upon a BRAF inhibitor backbone is the therapeutic future. Appropriate regulation of the cell cycle is critical for preventing progression to cancer, however the vast majority of melanomas harbor alterations in cell cycle and p53 regulatory pathways such as loss of CDKN2A and overexpression of CDK4, cyclin D1, MDM2 and MDM4. The alterations in these pathways appear to play critical roles in the development of melanoma and may represent potential therapeutic targets. Furthermore, some studies suggest that there is interaction between BRAF, key cell cycle proteins and the p53 pathway and that BRAF inhibitors may synergize with treatments that either enhance p53 function or inhibit CDK activity. Preclinical studies in melanoma have shown the potential efficacy of enhancing p53 function through inhibition of MDM2 or MDM4. Other studies have shown potential benefit in antagonizing CDK activity through use of small molecule inhibitors. However, targeting p53 and CDK function in melanoma is at an early stage and additional studies are needed particularly to understand the effects of combining these therapies with BRAF inhibition. Furthermore, clinical trials testing these therapeutic combinations specifically in melanoma patients are also needed to determine if the results of preclinical studies can be translated into beneficial effects in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14.

    Google Scholar 

  2. Abdullah C, Wang X, Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle. 2011;10:977–88.

    Google Scholar 

  3. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 2005;65:4005–11.

    Google Scholar 

  4. Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012;22:211–19.

    Google Scholar 

  5. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ, Vousden KH. Phosphorylation of HDM2 by Akt. Oncogene. 2002;21:1955–62.

    Google Scholar 

  6. Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC cancer. 2011;11:203.

    Google Scholar 

  7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    Google Scholar 

  8. Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Stromblad S. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle. 2011;10:301–07.

    Google Scholar 

  9. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol. 2001;21:2144–53.

    Google Scholar 

  10. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 1996;56:5475–83.

    Google Scholar 

  11. Berger JH, Bardeesy N. Modeling INK4/ARF tumor suppression in the mouse. Curr Mol Med. 2007;7:63–75.

    Google Scholar 

  12. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc. 2007;129:2456–2457.

    Google Scholar 

  13. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer cell. 2010;18:411–22.

    Google Scholar 

  14. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene. 2005;24:3459–71.

    Google Scholar 

  15. Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene. 2007;26:1056–66.

    Google Scholar 

  16. Bloethner S, Scherer D, Drechsel M, Hemminki K, Kumar R. Malignant melanoma—a genetic overview. Actas dermo-sifiliograficas. 2009;100(Suppl 1):38–51.

    Google Scholar 

  17. Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, Kalurupalle S, Blagosklonny MV, Roninson IB. p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene. 2007;26:6954–58.

    Google Scholar 

  18. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–73.

    Google Scholar 

  19. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs. 2004;22:315–22.

    Google Scholar 

  20. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671–82.

    Google Scholar 

  21. Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther. 2012;13:451–7.

    Google Scholar 

  22. Canepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB life. 2007;59:419–26.

    Google Scholar 

  23. Caporali S, Alvino E, Starace G, Ciomei M, Brasca MG, Levati L, Garbin A, Castiglia D, Covaciu C, Bonmassar E, et al. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol Res: off J Italian Pharmacol Soc. 2010;61:437–48.

    Google Scholar 

  24. Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, et al. Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem pharmacol. 2012;84:598–611.

    Google Scholar 

  25. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 1997;57:4868–75.

    Google Scholar 

  26. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

    Google Scholar 

  27. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res: MCR. 2007;5:1133–45.

    Google Scholar 

  28. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20:2149–82.

    Google Scholar 

  29. Chinnam M, Goodrich DW. RB1, development, and cancer. Curr Top Dev Biol. 2011;94:129–69.

    Google Scholar 

  30. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet. 2005;37:745–49.

    Google Scholar 

  31. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011;137:1409–18.

    Google Scholar 

  32. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, et al. Melanoma. J Natl Compr Canc Netw: JNCCN. 2009;7:250–75.

    Google Scholar 

  33. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS. 2007;115:1161–76.

    Google Scholar 

  34. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene. 2004;23:5968–77.

    Google Scholar 

  35. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer cell. 2009;15:294–303.

    Google Scholar 

  36. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009;16:36–43.

    Google Scholar 

  37. Dovey M, White RM, Zon LI. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Zebrafish. 2009;6:397–404.

    Google Scholar 

  38. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer cell. 2004;6:565–76.

    Google Scholar 

  39. Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82:201–09.

    Google Scholar 

  40. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T. Schmidt M, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER + /HER2- advanced breast cancer (BC). Abstracts: 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec 4–8, 2012, San Antonio, TX. Cancer research. 2012. 72(Suppl 3): Abstract nr S1-6.

    Google Scholar 

  41. Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 1996;56:5023–32.

    Google Scholar 

  42. Foijer F, Wolthuis RM, Doodeman V, Medema RH, te Riele H. Mitogen requirement for cell cycle progression in the absence of pocket protein activity. Cancer cell. 2005;8:455–66.

    Google Scholar 

  43. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012;18(8):1239–47

    Google Scholar 

  44. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol. 2001;54:229–35.

    Google Scholar 

  45. Ghosh JC, Altieri DC. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res: offic J Am Assoc Cancer Res. 2005;11:4580–8.

    Google Scholar 

  46. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, Spitz F, Schuchter L, Elder D. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004;22:3668–76.

    Google Scholar 

  47. Giuliano S, Ohanna M, Ballotti R, Bertolotto C. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res. 2011;24:295–308.

    Google Scholar 

  48. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007;109:455–64.

    Google Scholar 

  49. Golias CH, Charalabopoulos A, Charalabopoulos K. Cell proliferation and cell cycle control: a mini review. Int J Clin Pract. 2004;58:1134–41.

    Google Scholar 

  50. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–56.

    Google Scholar 

  51. Gordon GM, Du W. Conserved RB functions in development and tumor suppression. Protein Cell. 2011;2:864–78.

    Google Scholar 

  52. Grafstrom E, Egyhazi S, Ringborg U, Hansson J, Platz A. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res: offic J Am Assoc Cancer Res. 2005;11:2991–7.

    Google Scholar 

  53. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer. 2006;95:496–505.

    Google Scholar 

  54. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV, et al. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A. 2007;104:10968–73.

    Google Scholar 

  55. Hacker E, Muller HK, Irwin N, Gabrielli B, Lincoln D, Pavey S, Powell MB, Malumbres M, Barbacid M, Hayward N, et al. Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res. 2006;66:2946–52.

    Google Scholar 

  56. Halaban R. Rb/E2F: a two-edged sword in the melanocytic system. Cancer Metastasis Rev. 2005;24:339–56.

    Google Scholar 

  57. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14–3–3 sigma is a p53-regulated inhibitor of G2/M progression. Mol cell. 1997;1:3–11.

    Google Scholar 

  58. Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet. 2002;11:1273–9.

    Google Scholar 

  59. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Medicine. 2010;363:711–23.

    Google Scholar 

  60. Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, Muller CS, Schrama D, Wischhusen J, Becker JC. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PloS one. 2011;6:e22096.

    Google Scholar 

  61. Hu W, Feng Z, Levine AJ. The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer. 2012;3:199–208.

    Google Scholar 

  62. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15–21.

    Google Scholar 

  63. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol. 2009;4:551–79.

    Google Scholar 

  64. Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol. 2012;132:356–64.

    Google Scholar 

  65. John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, et al. GSK3beta inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol. 2012;132:2818–27.

    Google Scholar 

  66. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig HH, et al. P276–00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007;6:926–34.

    Google Scholar 

  67. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436–40.

    Google Scholar 

  68. Kannan K, Sharpless NE, Xu J, O’Hagan RC, Bosenberg M, Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A. 2003;100:1221–5.

    Google Scholar 

  69. Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2012;2:15.

    Google Scholar 

  70. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 2001;413:83–6.

    Google Scholar 

  71. Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 2012;18:124–31.

    Google Scholar 

  72. Kumar R, Lundh Rozell B, Louhelainen J, Hemminki K. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas. Int J Cancer. 1998a;75:193–8.

    Google Scholar 

  73. Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes, chromosomes Cancer. 1998b;23:273–7.

    Google Scholar 

  74. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–8.

    Google Scholar 

  75. Kumar A, Holden SA, Chafai-Fadela K, Ram S, Menon K. Abstract 2874: kevetrin targets both MDM2-p53 and Rb-E2F pathways in tumor suppression. AACR 103rd Annual Meeting, Mar 31-Apr 4, 2012, Chicago, IL. Cancer Res. 2012;72 (Suppl 1).

    Google Scholar 

  76. de Lange J, Teunisse AF, Vries MV, Lodder K, Lam S, Luyten GP, Bernal F, Jager MJ, Jochemsen AG. High levels of Hdmx promote cell growth in a subset of uveal melanomas. Am J Cancer Res. 2012;2:492–507.

    Google Scholar 

  77. Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, Ribas A, Sondak VK. SWOG S0826: a phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. Abstract: 8521, 2012 ASCO Annual Meeting, Jun 1–5, 2012, Chicago, IL. J Clin Oncol 2012;30(suppl; abstr 8521).

    Google Scholar 

  78. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547–66.

    Google Scholar 

  79. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006 444:61–6.

    Google Scholar 

  80. Li J, Xu M, Yang Z, Li A, Dong J Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Investig. 2010;28:350–6.

    Google Scholar 

  81. Liu Q, Mier JW, Panka DJ. Differential modulatory effects of GSK-3beta and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Mol Cancer. 2011;10:115.

    Google Scholar 

  82. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist updat: Rev comment antimicrob anticancer chemother. 2007;10:13–29.

    Google Scholar 

  83. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166.

    Google Scholar 

  84. Mancini F, Di Conza G, Moretti F. MDM4 (MDMX) and its transcript variants. Curr Genomics. 2009;10:42–50.

    Google Scholar 

  85. Manning AL, Dyson NJ. pRB, a tumor suppressor with a stabilizing presence. Trends Cell Biol. 2011;21:433–41.

    Google Scholar 

  86. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J cell Sci. 2007;120:371–8.

    Google Scholar 

  87. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223–1.

    Google Scholar 

  88. Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene. 2004;23:2347–56.

    Google Scholar 

  89. Merkel CA, da Silva Soares RB, de Carvalho AC, Zanatta DB, Bajgelman MC, Fratini P, Costanzi-Strauss E, Strauss BE. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC cancer. 2010;10:316.

    Google Scholar 

  90. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer cell. 2003;4:181–9.

    Google Scholar 

  91. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–4.

    Google Scholar 

  92. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene. 2008;27:877–95.

    Google Scholar 

  93. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51–65.

    Google Scholar 

  94. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotech. 2012;2012:170325.

    Google Scholar 

  95. Mohapatra S, Coppola D, Riker AI, Pledger WJ Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma. Mol Cancer Res: MCR. 2007;5:145–51.

    Google Scholar 

  96. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, Horner J, Depinho RA, Sharpless NE. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene. 2010;29:5809–17.

    Google Scholar 

  97. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203–6.

    Google Scholar 

  98. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L, Bosenberg MW. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer. 2006;45:447–54.

    Google Scholar 

  99. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753–6.

    Google Scholar 

  100. Ozenne P, Eymin B, Brambilla E, Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer. 2010;127:2239–47.

    Google Scholar 

  101. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G.. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001;29:92–5.

    Google Scholar 

  102. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol: CB. 2005;15:249–54.

    Google Scholar 

  103. Pho L, Grossman D, Leachman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr opin oncolo. 2006;18:173–9.

    Google Scholar 

  104. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20.

    Google Scholar 

  105. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C, Osman I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 2001;61:7642–6.

    Google Scholar 

  106. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000.

    Google Scholar 

  107. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet oncol. 2012;13:1133–40.

    Google Scholar 

  108. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, Mila M, Kefford RF. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene. 2001;20:5543–7.

    Google Scholar 

  109. Robinson WA, Miller TL, Harrold EA, Bemis LT, Brady BM, Nelson RP. The effect of flavopiridol on the growth of p16 + and p16- melanoma cell lines. Melanoma Res. 2003;13:231–8.

    Google Scholar 

  110. Rotolo S, Diotti R, Gordon RE, Qiao RF, Yao Z, Phelps RG, Dong J. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Int J Cancer. 2005;115:164–9.

    Google Scholar 

  111. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochimica et biophysica acta. 1998;1378:F115–77.

    Google Scholar 

  112. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 2009;28:2925–39.

    Google Scholar 

  113. Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther. 2002a;9:807–12.

    Google Scholar 

  114. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002b;62:3200–6.

    Google Scholar 

  115. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27–37.

    Google Scholar 

  116. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576:22–38.

    Google Scholar 

  117. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 2001;413:86–91.

    Google Scholar 

  118. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene. 2003;22:5055–9.

    Google Scholar 

  119. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene. 2004;23:379–85.

    Google Scholar 

  120. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Google Scholar 

  121. Simboeck E, Ribeiro JD, Teichmann S, Di Croce L. Epigenetics and senescence: learning from the INK4-ARF locus. Biochem Pharmacol. 2011;82:1361–70.

    Google Scholar 

  122. Smalley KS, McArthur GA. The current state of targeted therapy in melanoma: this time it’s personal. Seminars in oncology. 2012;39:204–14.

    Google Scholar 

  123. Smalley KS, Sondak VK. Skin cancer: targeted therapy for melanoma: is double hitting a home run? Nature reviews Clin Oncol. 2012;10:5–6.

    Google Scholar 

  124. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006;5:1136–44.

    Google Scholar 

  125. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 2007;67:209–17.

    Google Scholar 

  126. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7:2876–83.

    Google Scholar 

  127. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res. 2009;69:3241–4.

    Google Scholar 

  128. Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A. 2001;98:13312–7.

    Google Scholar 

  129. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540°C > T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol. 2002;161:229–237.

    Google Scholar 

  130. Tang L, Li G, Tron VA, Trotter MJ, Ho VC. Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res. 1999;9:148–54.

    Google Scholar 

  131. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, et al. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010;23:781–94.

    Google Scholar 

  132. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6:909–23.

    Google Scholar 

  133. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39:1476–82.

    Google Scholar 

  134. Tortelli T Jr., Chammas R, Chellappan S. Abstract 5598: Interaction between BRAF inhibitor PLX-4720 and CDK inhibitors can sensitize melanoma cells with BRAF V600E mutation. AACR 103rd Annual Meeting, Mar 31-Apr 4, 2012, Chicago, IL. Cancer research. 2012;72(Suppl 1)

    Google Scholar 

  135. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26:1131–55.

    Google Scholar 

  136. Tseng HY, Jiang CC, Croft A, Tay KH, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol Cancer Ther. 2010;9:3363–74.

    Google Scholar 

  137. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle. 2004;3:419–21.

    Google Scholar 

  138. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC, Nikolovska-Coleska Z, Bengtson A, Nair R, Elder JT, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006;66:11348–59.

    Google Scholar 

  139. Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene. 2012;31:828–41.

    Google Scholar 

  140. Vousden KH, Prives C. Blinded by the Light: the growing complexity of p53. Cell. 2009;137:413–31.

    Google Scholar 

  141. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012;26:1055–69.

    Google Scholar 

  142. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res: MCR. 2009;7:1–11.

    Google Scholar 

  143. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. Virtually 100 % of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer. 1998;22:157–63.

    Google Scholar 

  144. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25:52–8.

    Google Scholar 

  145. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994;7:480–4.

    Google Scholar 

  146. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol. 2005;125:1242–51.

    Google Scholar 

  147. Yu BD, Becker-Hapak M, Snyder EL, Vooijs M, Denicourt C, Dowdy SF. Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proc Natl Acad Sci U S A. 2003;100:14881–86.

    Google Scholar 

  148. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, et al. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol. 2009;174:2367–77.

    Google Scholar 

  149. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ Jr. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene. 1999;18:2892–900.

    Google Scholar 

  150. Zhao Y, Zhang Y, Yang Z, Li A, Dong J. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 2008;370:509–13.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, 33612, Tampa, FL, USA

    Keiran SM Smalley PhD

  2. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

    Dale Han & Keiran SM Smalley PhD

Authors
  1. Dale Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keiran SM Smalley PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keiran SM Smalley PhD .

Editor information

Editors and Affiliations

  1. Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

    Ryan J. Sullivan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Han, D., Smalley, K. (2015). Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy. In: Sullivan, R. (eds) BRAF Targets in Melanoma. Cancer Drug Discovery and Development, vol 82. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2143-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2143-0_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2142-3

  • Online ISBN: 978-1-4939-2143-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation